MELODY EVANS: Open Payments
NPI 1174050447 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,623 in 71 payments from 18 companies in 2025. Trend: 2023 $597 · 2024 $2,390 · 2025 $1,623
Food & beverage: $1,623
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 10 | $256 |
| GlaxoSmithKline, LLC. | 12 | $236 |
| Verona Pharma, Inc. | 13 | $220 |
| AstraZeneca Pharmaceuticals LP | 7 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $146 |
| GENZYME CORPORATION | 5 | $143 |
| Actelion Pharmaceuticals US, Inc. | 4 | $90 |
| Mallinckrodt Hospital Products Inc. | 3 | $79 |
| United Therapeutics Corporation | 3 | $68 |
| Amgen Inc. | 2 | $48 |
Products named: DUPIXENT, Ohtuvayre, NUCALA, TEZSPIRE, GLASSIA, Tyvaso, OPSUMIT, ACTHAR.
Industry payments across MD — which companies pay providers there.
